Royalty Pharma plc

RPRX

GB00BMVP7Y09

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâs Trikafta, GSKâs Trelegy, Rocheâs Evrysdi, Johnson & Johnsonâs Tremfya, Biogenâs Tysabri and Spinraza, AbbVie and Johnson & Johnsonâs Imbruvica, Astellas and Pfizerâs Xtandi, Novartisâ Promacta, Pfizerâs Nurtec ODT and Gileadâs Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Sector

Pharmaceuticals

Calendar

09/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Royalty Pharma plc

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.28 USD

Average target price

45.88 USD

Spread / Average Target

+62.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROYALTY PHARMA PLC	+0.68%	12.75B
ELI LILLY AND COMPANY	+33.43%	700B
NOVO NORDISK A/S	+26.43%	569B
JOHNSON & JOHNSON	-5.12%	358B
MERCK & CO., INC.	+19.59%	330B
ABBVIE INC.	+4.89%	287B
ASTRAZENECA PLC	+14.32%	236B
NOVARTIS AG	+5.79%	202B
ROCHE HOLDING AG	-9.49%	197B
AMGEN INC.	+4.26%	161B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
28.28 ^USD	-0.74%		+2.09%	+0.68%

03/05	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	MT
17/04	Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	MT

Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	03/05	MT
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	18/04	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	17/04	CI
Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	09/04	MT
Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	05/03
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	20/02	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	20/02	MT
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	15/02	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	15/02	MT
Transcript : Royalty Pharma plc, Q4 2023 Earnings Call, Feb 15, 2024	15/02
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	15/02	MT
Novartis wants to swallow Morphosys - access to beacon of hope	06/02	DP
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16	19/01	MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024	19/01	CI
Transcript : Royalty Pharma plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	09/01
Royalty Pharma Insider Sold Shares Worth $13,222,862, According to a Recent SEC Filing	05/01	MT
Royalty Pharma plc and Royalty Pharma Holdings Ltd Enters into Amendment No. 3 to the Amended and Restated Revolving Credit Agreement	28/12	CI
PureTech Health Provides Updates on Programs, Reports Strong Financial Position	20/12	MT
Morphosys raises more than 100 million euros with capital increase	14/12	DP
The only way is up…	12/12
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	12/12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	12/12
Transcript : Royalty Pharma plc Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 03:00 PM	29/11